×

Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments

  • US 9,220,776 B2
  • Filed: 03/29/2012
  • Issued: 12/29/2015
  • Est. Priority Date: 03/31/2011
  • Status: Active Grant
First Claim
Patent Images

1. A stable lyophilized pharmaceutical formulation of an anti-human PD-1 antibody, wherein the formulation made by lyophilizing an aqueous solution comprising:

  • a) 25-100 mg/mL of the anti-human PD-1 antibody;

    b) about 70 mg/mL sucrose;

    c) about 0.2 mg/mL polysorbate 80; and

    d) about 10 mM Histidine buffer at about pH 5.0-pH 6.0, andwherein the antibody, comprises;

    i) a light chain comprising amino acid residues 20 to 237 of SEQ ID NO;

    36; and

    ii) a heavy chain comprising amino acid residues 20 to 466 of SEQ ID NO;

    31.

View all claims
  • 2 Assignments
Timeline View
Assignment View
    ×
    ×